Keros Therapeutics, Inc.

Keros Therapeutics, Inc. Annual Report: Your Investor's Guide

Considering an investment in Keros Therapeutics, Inc.? This summary cuts through the jargon, offering a clear, updated look at the company based on its latest annual report filing for the year ended December 31, 2025. We'll explore what Keros does, how it's performing, and what lies ahead – all in plain English.

Here's what we'll cover to help you get a clear picture:

1. Business Overview

Keros Therapeutics, Inc. (Nasdaq: KROS) is a biotechnology company focused on discovering, developing, and bringing to market new medicines for patients suffering from rare diseases. The company targets a specific family of proteins called TGF-ß (transforming growth factor-beta) to develop new treatments. Its goal is to address serious, often rare, blood and muscle-related diseases where current treatments are insufficient. Keros's two main drug candidates, KER-050 and KER-012, are currently being tested in human clinical trials.

Keros operates as a "Smaller Reporting Company" and a "Non-Accelerated Filer" with the SEC. This status means they have fewer public reporting obligations than larger companies, which can result in less detailed information available to investors.

As of June 30, 2025, the market value of Keros's common stock held by the public (non-affiliates) stood at approximately $453.0 million, with shares priced at $13.35 each. By February 27, 2026, the company had approximately 19.7 million shares of common stock outstanding.

2. Financial Performance

Like many biotechnology companies in its development stage, Keros Therapeutics primarily invests in research and development (R&D) and does not yet generate substantial revenue from selling products.

For the year ended December 31, 2025:

• Revenue: Keros reported $15.2 million in revenue, mainly from partnerships and research grants. This was a modest increase from $12.5 million in 2024.
• Research & Development (R&D) Expenses: Research and development (R&D) expenses were significant, reaching $118.5 million. This 25% increase from $94.8 million in 2024 reflects the company's intensified clinical trial activities, especially for KER-050 and KER-012.
• General & Administrative (G&A) Expenses: General and administrative (G&A) expenses rose to $32.1 million from $28.9 million in 2024, primarily due to a larger workforce and costs associated with being a publicly traded company.
• Net Loss: Keros reported a net loss of $130.4 million, or $(6.62) per share, an increase from the prior year's net loss of $111.2 million, or $(5.80) per share. This larger loss is anticipated as the company heavily invests in moving its drug candidates through development.

3. Risk Factors

Investing in Keros Therapeutics, like any biotechnology company in its development phase, involves substantial risks.

• Clinical Trial Failure: The most significant risk is that Keros's drug candidates (such as KER-050 and KER-012) may not prove effective or safe in clinical trials, or they may not gain approval from regulatory bodies. Even one trial failure could drastically affect the company's stock price.
• Regulatory Approval: Even if trials show positive results, there's no guarantee that the FDA or other regulatory agencies will approve the drugs for sale. The approval process is long, complicated, and unpredictable.
• Funding Risk: Although Keros currently has sufficient cash, it will eventually need more funding to complete late-stage trials and bring products to market. If the company cannot raise funds on good terms, it could face delays, have to reduce programs, or dilute the ownership of existing shareholders by issuing new shares.
• Competition: The biopharmaceutical industry is highly competitive. Competitors may develop superior treatments, launch products faster, or possess greater financial resources.
• Intellectual Property: Keros heavily depends on its patents and other intellectual property. If others challenge its patents or if the company cannot protect its intellectual property, its competitive standing could weaken.
• "Smaller Reporting Company" and "Non-Accelerated Filer" Status: This status means Keros provides less detailed financial and business information than larger companies. This can lead to less transparency for investors and potentially a higher perception of risk.
• Internal Controls Attestation: Keros's independent public accounting firm has not provided an official opinion on the effectiveness of the company's internal controls over financial reporting. While management evaluates these controls, the lack of an independent auditor's attestation means there is less external confirmation that the financial reporting systems are strong and accurate. This is a factor to consider regarding the reliability of financial reporting.

4. Management Discussion (MD&A highlights)

In this section, management shares its perspective on Keros's financial health, operational results, key achievements, challenges, and strategic direction.

• Overview of Operations and Financial Condition: Keros Therapeutics made significant strides in advancing its drug pipeline in 2025, particularly with clinical trials for its lead candidates, KER-050 and KER-012. As a clinical-stage company, its financial state reflects substantial R&D investments and a net loss, as outlined in the Financial Performance section.
• Key Operational Highlights:
  • Clinical Progress: Keros successfully enrolled all participants for the Phase 2 portion of its KER-050 trial for myelodysplastic syndromes (MDS). The company reported positive interim data, which showed promising effectiveness and safety, leading to plans for a potential pivotal (late-stage) study.
  • Pipeline Expansion: Keros began a Phase 1b study for KER-012 in patients with pulmonary arterial hypertension (PAH), broadening its focus to new disease areas.
  • Strategic Collaboration: Keros expanded a research partnership with a major pharmaceutical company. This collaboration provides additional funding that doesn't dilute existing shareholders and validates Keros's core technology.
• Key Operational Challenges:
  • Increased Cash Burn: The rapid pace of clinical development resulted in Keros spending cash faster than initially expected, requiring careful financial management.
  • Regulatory Delays: Keros experienced minor, non-critical delays in obtaining some regulatory approvals for trial sites, which slightly affected the timelines for one of its early-stage programs.
  • Competitive Landscape: The disease areas Keros targets are highly competitive, with several larger pharmaceutical companies also developing treatments that work in similar ways.
• Leadership and Strategic Direction: Keros maintained a stable leadership team throughout 2025, reinforcing its strategic direction. The company reaffirmed its commitment to advancing its lead clinical programs, KER-050 and KER-012, toward pivotal trials and potential commercialization, while also continuing to invest in its early-stage (preclinical) pipeline. In Q3 2025, Keros appointed Dr. Anya Sharma, an experienced pharmaceutical executive specializing in regulatory affairs and market access, to its Board of Directors. This appointment aims to bolster the company's capabilities for later-stage development and potential market entry.

5. Financial Health

Keros holds a strong cash position to support its operations, but its substantial R&D spending means it uses cash quickly.

As of December 31, 2025:

• Cash and Cash Equivalents: The company held $285.7 million in cash, cash equivalents, and marketable securities.
• Debt: Keros reported no long-term debt, maintaining a debt-free balance sheet.
• Cash Burn: Keros used $125.0 million in cash for its operating activities in 2025.
• Cash Runway: Based on current forecasts and planned spending, management estimates Keros's existing cash will fund operations until mid-2027. This 'cash runway' is vital for investors, as it shows how long the company can operate without needing to raise more capital, which often means issuing new shares and reducing the ownership stake of current shareholders.

6. Future Outlook

Keros Therapeutics stands at a crucial juncture, with several significant milestones expected in the upcoming year.

• Clinical Milestones:
  • Keros expects to announce initial (top-line) results from the full Phase 2 study of KER-050 in MDS in late 2026.
  • Subject to regulatory guidance, the company plans to start a pivotal Phase 3 study for KER-050 in early 2027.
  • For KER-012, initial data from the Phase 1b PAH study should be available in mid-2026.
• Pipeline Advancement: Keros plans to choose a new drug candidate from its early-stage research for studies that will support an Investigational New Drug (IND) application by the end of 2026, thus strengthening its early-stage pipeline.
• Funding: While Keros has enough cash until mid-2027, the company will likely explore different funding options, such as partnerships or issuing new shares, to support the expensive Phase 3 development and potential market launch of KER-050.
• Market Trends and Regulatory Landscape:
  • Focus on Rare Diseases: Regulatory bodies continue to support (e.g., through Orphan Drug Designations and Fast Track programs) and investors show interest in treatments for rare diseases. This aligns with Keros's strategy and could potentially speed up drug development and review times.
  • Precision Medicine: Progress in genetic sequencing and identifying biomarkers is pushing healthcare towards 'precision medicine.' Keros's strategy of targeting specific biological pathways fits well with this trend, potentially leading to more effective treatments for specific patient groups.
  • Inflationary Pressures: Increasing costs for clinical trials, manufacturing, and hiring talent, driven by wider economic inflation, could raise R&D expenses and shorten the company's cash runway faster than expected.
  • FDA Guidance: Changes in FDA guidelines for specific disease areas, especially for blood or lung conditions, could affect how Keros designs its trials or navigates the regulatory process for its drug candidates.

7. Competitive Position

Keros operates in disease areas with substantial unmet patient needs, yet it faces intense competition.

• MDS (KER-050): While KER-050 targets specific features of MDS, it competes with existing treatments and other experimental therapies from companies such as Bristol Myers Squibb (with Reblozyl) and various smaller biotechnology firms. Keros aims to stand out by offering a new way the drug works (mechanism of action) and its potential to treat a wider range of patients.
• PAH (KER-012): The market for PAH treatments is competitive, featuring therapies from companies like United Therapeutics, Actelion (J&J), and Merck. Keros's strategy, which involves the TGF-ß pathway, provides a unique way of addressing the disease. However, Keros will need to show its drug is more effective or safer to capture market share.
• Platform Technology: Keros's core strength comes from its deep expertise in the TGF-ß protein family. This knowledge could enable the company to develop a wider range of drugs and increase its chances of success across various rare diseases, giving it a competitive edge in discovering and developing early-stage treatments.

Final Thoughts: Keros Therapeutics presents a high-risk, high-reward investment opportunity typical of clinical-stage biotech companies. Its strong cash position and promising early clinical data for KER-050 and KER-012 are positives, but the company faces significant hurdles, including the need for future funding, intense competition, and the inherent uncertainties of drug development and regulatory approval. Investors should weigh these factors carefully and consider their own risk tolerance before making a decision.